fda stop compounding semaglutide Compound versions of GLP-1 drugs for weight loss halted by Despite FDA ruling, compounded GLP-1s

Pfizer has said it expects pills to eventually capture about a third of the obesity drug market, which is predicted to grow to about $130 billion by the end of the decade

Arch Histol Cytol 2003;66:253-260

Accessibility Challenges with Prescription Options Despite their proven effectiveness, prescription GLP 1 drugs face several barriers that limit patient access: Cost considerations : Monthly expenses can range from $800-$1,200 without insurance coverage, making them unaffordable for many individuals

US domestic only

GLP-1 agonists work by regulating appetite, slowing digestion, and helping the body manage blood sugarresulting in significant, often rapid, weight loss

Tirzepatide Tirzepatide GLP-1 is a dual-action metabolic therapy that supports weight control by improving insulin sensitivity, reducing appetite, and enhancing satiety